Osiris Therapeutics (OSIR) was notified that its PROCHYMAL received FDA ‘Fast Track’designation, expediting thedevelopment of the stem cell treatment for Crohn’s Disease that fails to respond to standard therapies. This takes it to Phase III clinical trials, which will be the last trial stage prior to seeking FDA Approval if resukts are successful. OSIR shares are up almost 5% at$26.30 in after-hours and shares traded 3-times normal volume; the 52 week trading band is $9.84 to $27.93. OSIR is a recently public company that is up some 150% since the August IPO and its market cap is $685 now million before the after-hours pop. Jefferies just downgraded this on valuation to a Hold last week, so much of this may already be refelcted in today’s prices.
Jon C. Ogg
January 8, 2007
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
